SOURCE: Curidium Medica PLC

April 24, 2008 02:14 ET

Curidium to Present at the Ingenuity Systems European User Group Meeting

LONDON--(Marketwire - April 24, 2008) - Curidium Medica plc (LSE: CUR) ("Curidium" or the "Company"), the personalized medicine company focused on bringing the right drug to the right patient, today announced that Dave Michalovich, Ph.D., Head of Drug Target Research, will be presenting at the Ingenuity Systems European User Group Meeting in France on 25 April at 1:15pm local time at Sofitel Le Mediterranee, Cannes, France.

Dr. Michalovich will give a presentation entitled "Patient Subpopulations in Schizophrenia and Bipolar Disorder: Understanding Underlying Disease Mechanisms to Identify Potentially More Effective Treatments."

For further information, please contact:
Rob Smith
+44 (0)20 7383 5345
Finance Director
Curidium Medica plc

Charlie Cunningham
+44 (0)20 7600 1658
JM Finn Capital Markets Ltd

Billy Clegg / Edward Westropp / Annie Evangeli
+44 (0)20 7831 3113
Financial Dynamics

Notes to Editors

Curidium Medica

Curidium is a personalized medicine company identifying targeted medicines and companion diagnostics to treat patients more effectively.

Curidium's initial focus on diseases of the Central Nervous System has resulted in the identification of a blood diagnostic test, PsychINDx™, which classifies patients with schizophrenia/bipolar disorder into four subgroups. PsychINDx™ may have the potential to improve the treatment of patients with schizophrenia/bipolar disorder.

Many chronic human diseases are heterogeneous and their patient populations consist of mixed subgroups. Through the use of its proprietary analysis tool, Homomatrix®, Curidium aims to reveal different patient subgroups characterized by distinct underlying disease mechanisms potentially leading to the identification of:

1. Diagnostics for better identification and treatment within heterogeneous disease populations.

2. Improved therapies identified through novel drug targets.

3. Personalized medicines using companion diagnostics and targeted treatments.

Curidium aims to continue to use this approach to improve patient treatments in a variety of therapeutic areas. Further information on Curidium can be found at the Company's website: www.curidium.com.

Curidium Medica plc (c) 2001-2008. All rights reserved.

Studio 10, Tiger House, London WC1H 9BY, United Kingdom.

Email: info@curidium.com Tel.: +44 (0)20 7383 5345, Fax: +44 (0)20 7383 2973

                 This information is provided by RNS
        The company news service from the London Stock Exchange

Contact Information

  • For further information, please contact:
    Rob Smith
    +44 (0)20 7383 5345
    Finance Director
    Curidium Medica plc

    Charlie Cunningham
    +44 (0)20 7600 1658
    JM Finn Capital Markets Ltd

    Billy Clegg / Edward Westropp / Annie Evangeli
    + 44 (0)20 7831 3113
    Financial Dynamics